CMS Coverage Determination Guide: From NCD to LCD to Real Reimbursement

← Back to All Insights

FDA clearance and CMS coverage are different events with different timelines, different decision criteria, and different stakeholders. Many medical device companies build commercial models around "FDA clears it, payers will follow." That assumption no longer holds—if it ever did. Understanding how CMS actually makes coverage decisions is essential for any commercial strategy that depends on Medicare reimbursement.

The gap between FDA clearance and CMS coverage can be years, and the gap between CMS coverage and commercial payer coverage can be years more.

National vs Local Coverage Determinations

National Coverage Determinations (NCDs) apply across all Medicare jurisdictions and are issued by CMS centrally. Local Coverage Determinations (LCDs) are issued by Medicare Administrative Contractors (MACs)—each MAC covers a specific geographic region and can issue independent LCDs. Most medical devices and diagnostics are covered (or not covered) initially through LCDs, then potentially elevated to NCD status.

The Coverage Pathway Decision

Sponsors must decide whether to pursue NCD pathway (centralized review, broader coverage if successful, longer timeline) or LCD pathway (faster initial coverage, region-by-region buildout, more administrative overhead). The right choice depends on the device's clinical evidence base, the urgency of commercial launch, and the strength of physician demand at scale.

MolDx and the Diagnostic Coverage Pathway

The Palmetto MolDx program covers molecular diagnostic services across all MAC regions. It has its own coverage criteria, technical assessment process, and evidence standards. For genomic and biomarker diagnostics, the MolDx pathway is often the primary route to Medicare coverage. Diagnostics companies that misunderstand MolDx submission requirements lose 12-18 months in coverage delays.

Hospital Outpatient PPS and the APC

For procedures performed in hospital outpatient settings, the Hospital Outpatient Prospective Payment System (OPPS) and its Ambulatory Payment Classifications (APCs) determine the payment rate. Annual APC updates—and especially packaging changes that bundle the device into a procedure payment—can dramatically affect device economics. The 2024 rule changes around device-intensive APC packaging affected multiple device categories.

New Technology Add-On Payment

The New Technology Add-On Payment (NTAP) provides supplemental Medicare payment for breakthrough technologies during their early commercialization. NTAP is time-limited (typically 2-3 years) and requires specific eligibility criteria. Sponsors who plan around NTAP need to also plan for the transition off NTAP—and many do not.

Commercial Payer Coverage Lag

Commercial payers typically lag CMS coverage by 6-24 months and may apply different criteria. Some payers (Aetna, Anthem) tend to align with CMS; others (BCBS plans, particularly regional ones) develop independent positions. Modeling commercial coverage simply by reference to CMS status systematically over-estimates total payer access in the first 18 months post-coverage.

Reimbursement strategy is not a function of FDA clearance—it is a parallel discipline with its own decision frameworks, timelines, and stakeholders. Companies that integrate reimbursement strategy into product development from Series A onward consistently outperform those that treat coverage as a post-launch problem.